Combining dapagliflozin and oral semaglutide improves type 2 diabetes

A study in Pharmacological Research evaluated the efficacy of combining dapagliflozin and oral semaglutide in 1,335 type 2 diabetes patients. The combination therapy reduced glycated hemoglobin by 1.2%, outperforming dapagliflozin alone. It also improved body mass index, blood pressure, cholesterol, and glucose levels. The combination achieved 55% glycated hemoglobin near-normalization, making it a preferable alternative to conventional dapagliflozin therapy. The study suggests it may induce type 2 diabetes pharmacological remission in over 50% of patients.